GSAT vs MNKD vs UTHR vs IRDM

For growth investors, MannKind Corporation (MNKD) is the stronger pick with 22.

2% revenue growth year-over-year, versus 4. 9% for Iridium Communications Inc. (IRDM). United Therapeutics Corporation (UTHR) offers the better valuation at 20. 4x trailing P/E (19. 4x forward), making it the more compelling value choice. Analysts rate MannKind Corporation (MNKD) a "Buy" — based on 19 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

On trailing P/E, United Therapeutics Corporation (UTHR) is the cheapest at 20.

4x versus MannKind Corporation at 177. 5x. On forward P/E, United Therapeutics Corporation is actually cheaper at 19. 4x.

Over the past 5 years, Globalstar, Inc.

(GSAT) delivered a total return of +393. 8%, compared to -17. 2% for MannKind Corporation (MNKD). Over 10 years, the gap is even starker: IRDM returned +412. 1% versus MNKD's -46. 2%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), United Therapeutics Corporation (UTHR) is the lower-risk stock at 0.

19β versus Globalstar, Inc. 's 2. 08β — meaning GSAT is approximately 987% more volatile than UTHR relative to the S&P 500. On balance sheet safety, Globalstar, Inc. (GSAT) carries a lower debt/equity ratio of 151% versus 4% for Iridium Communications Inc. — giving it more financial flexibility in a downturn.

By revenue growth (latest reported year), MannKind Corporation (MNKD) is pulling ahead at 22.

2% versus 4. 9% for Iridium Communications Inc. (IRDM). On earnings-per-share growth, the picture is similar: United Therapeutics Corporation grew EPS 13. 1% year-over-year, compared to -195. 0% for Globalstar, Inc.. Over a 3-year CAGR, MNKD leads at 51. 8% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

United Therapeutics Corporation (UTHR) is the more profitable company, earning 41.

9% net margin versus -25. 2% for Globalstar, Inc. — meaning it keeps 41. 9% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: UTHR leads at 46. 9% versus -0. 4% for GSAT. At the gross margin level — before operating expenses — UTHR leads at 87. 9%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

On forward earnings alone, United Therapeutics Corporation (UTHR) trades at 19.

4x forward P/E versus 217. 8x for MannKind Corporation — 198. 4x cheaper on a one-year earnings basis. Analyst consensus price targets imply the most upside for MNKD: 97. 2% to $7. 00.

In this comparison, IRDM (1.

5% yield), GSAT (0. 1% yield) pay a dividend. MNKD, UTHR do not pay a meaningful dividend and should not be held primarily for income.

For long-horizon retirement investors, United Therapeutics Corporation (UTHR) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0.

19), +410. 0% 10Y return). Globalstar, Inc. (GSAT) carries a higher beta of 2. 08 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (UTHR: +410. 0%, GSAT: +201. 8%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

These companies operate in different sectors (GSAT (Communication Services) and MNKD (Healthcare) and UTHR (Healthcare) and IRDM (Communication Services)), which means they face different economic cycles, regulatory environments, and macro sensitivities — making direct comparison nuanced.

In terms of investment character: GSAT is a mid-cap quality compounder stock; MNKD is a small-cap high-growth stock; UTHR is a mid-cap quality compounder stock; IRDM is a small-cap quality compounder stock. IRDM pays a dividend while GSAT, MNKD, UTHR do not, making them suitable for different income and tax situations. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.